Dani Castillo, Medical Oncologist and Researcher, shared an update from Justin Moyers, Associate Professor at UC San Diego Health, on X, adding:
“Hands-on training session at UC San Diego Health upon new FDA approval for Tudriquev in melanoma.”
Quoting Justin Moyers:
“New approval in melanoma of Replimune’s vusolimogene oderparepvec-wtpg (Tudriqev, or RP1) comes just in time for our hands on training session next week!
Join us on 8/15 UC San Diego Health Moores Cancer Center.
Free CME a registration!”
This also can be interesting:
Third Time’s the Charm: FDA Approves Replimune’s Tudriqev (RP1) for Advanced Melanoma
